Certified Researchers

Helicobacter Pylori Test Market Summary

As per MRFR analysis, the Helicobacter Pylori Test Market Size was estimated at 3234.48 USD Million in 2024. The Helicobacter Pylori Test industry is projected to grow from 3418.91 USD Million in 2025 to 5952.8 USD Million by 2035, exhibiting a compound annual growth rate (CAGR) of 5.7% during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Helicobacter Pylori Test Market is experiencing robust growth driven by technological advancements and increasing health awareness.

Technological advancements in testing methodologies are enhancing the accuracy and efficiency of Helicobacter Pylori diagnostics.
North America remains the largest market, while the Asia-Pacific region is emerging as the fastest-growing area for Helicobacter Pylori testing.
The Urea Breath Test continues to dominate the market, whereas the Stool Antigen Test is witnessing rapid growth due to its non-invasive nature.
Rising incidence of Helicobacter Pylori infections and increased focus on gastrointestinal health are key drivers propelling market expansion.

Market Size & Forecast

2024 Market Size	3234.48 (USD Million)
2035 Market Size	5952.8 (USD Million)
CAGR (2025 - 2035)	5.7%

Major Players

Abbott Laboratories (US), Thermo Fisher Scientific (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Hologic (US), Meridian Bioscience (US), Genomica (ES), Eiken Chemical (JP)

Our Impact

Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals

Partnering with 2000+ Global Organizations Each Year

30K+ Citations by Top-Tier Firms in the Industry

Helicobacter Pylori Test Market Trends

The Helicobacter Pylori Test Market is currently experiencing notable developments driven by increasing awareness of gastrointestinal health and the rising prevalence of related disorders. As more individuals seek diagnostic solutions for conditions linked to Helicobacter pylori infections, the demand for accurate and efficient testing methods appears to be on the rise. This trend is further supported by advancements in technology, which enhance the reliability and speed of test results, thereby improving patient outcomes. Additionally, healthcare providers are increasingly recognizing the importance of early detection and treatment of H. pylori infections, which may lead to serious complications if left unaddressed. Moreover, the market landscape is evolving with the introduction of novel testing methodologies, including non-invasive options that appeal to a broader patient demographic. These innovations not only cater to the needs of healthcare professionals but also align with patient preferences for less invasive procedures. As the global focus on preventive healthcare intensifies, the Helicobacter Pylori Test Market is poised for continued growth, driven by a combination of technological advancements, heightened awareness, and an increasing emphasis on early diagnosis and treatment strategies.

Technological Advancements in Testing

The Helicobacter Pylori Test Market is witnessing a surge in innovative testing technologies. These advancements include the development of rapid diagnostic tests and non-invasive methods, which enhance the accuracy and speed of results. Such innovations are likely to improve patient compliance and satisfaction.

Growing Awareness of Gastrointestinal Health

There is a noticeable increase in public awareness regarding gastrointestinal health issues, particularly those associated with Helicobacter pylori infections. This heightened awareness is driving more individuals to seek testing, thereby expanding the market and encouraging healthcare providers to prioritize early diagnosis.

Shift Towards Preventive Healthcare

The global healthcare landscape is gradually shifting towards preventive measures, with a focus on early detection of diseases. This trend is influencing the Helicobacter Pylori Test Market, as more healthcare systems integrate routine screening for H. pylori infections into their preventive health strategies.

Helicobacter Pylori Test Market Drivers

Market Growth Projections

The Global Helicobacter Pylori Test Market Industry is projected to experience substantial growth over the next decade. With a market value of 3.23 USD Billion in 2024, it is anticipated to reach 5.95 USD Billion by 2035, reflecting a robust CAGR of 5.71% from 2025 to 2035. This growth trajectory indicates a rising demand for effective diagnostic solutions and highlights the increasing recognition of Helicobacter Pylori as a critical public health concern. The market's expansion is likely to be fueled by advancements in testing technologies, heightened awareness, and supportive regulatory frameworks.

Regulatory Support and Guidelines

Support from regulatory bodies and the establishment of clinical guidelines for Helicobacter Pylori testing bolster the Global Helicobacter Pylori Test Market Industry. Organizations such as the World Health Organization advocate for the testing and treatment of Helicobacter Pylori infections, influencing healthcare policies worldwide. This regulatory backing encourages healthcare providers to adopt testing protocols, thereby increasing market penetration. As guidelines evolve and emphasize the importance of early detection, the market is expected to experience sustained growth, driven by compliance with these recommendations.

Increase in Gastrointestinal Disorders

The rising prevalence of gastrointestinal disorders, such as gastritis and peptic ulcers, is a significant driver for the Global Helicobacter Pylori Test Market Industry. These conditions are often associated with Helicobacter Pylori infections, prompting healthcare professionals to recommend testing as a standard diagnostic procedure. As more individuals seek medical attention for gastrointestinal symptoms, the demand for reliable testing methods is expected to rise. This trend is likely to contribute to the market's growth, as healthcare systems prioritize effective diagnosis and management of these disorders.

Advancements in Diagnostic Technologies

Technological innovations in diagnostic methods are enhancing the accuracy and efficiency of Helicobacter Pylori testing. The Global Helicobacter Pylori Test Market Industry benefits from the introduction of non-invasive tests, such as breath tests and stool antigen tests, which are gaining traction among healthcare professionals. These advancements not only improve patient compliance but also reduce the burden on healthcare systems. As the market evolves, it is expected to grow at a CAGR of 5.71% from 2025 to 2035, potentially reaching 5.95 USD Billion by 2035, reflecting the increasing reliance on advanced diagnostic technologies.

Growing Awareness and Education Initiatives

Public health campaigns aimed at raising awareness about Helicobacter Pylori infections are crucial in driving the Global Helicobacter Pylori Test Market Industry. Educational initiatives by health organizations emphasize the importance of early detection and treatment of infections to prevent complications such as peptic ulcers and gastric cancer. This heightened awareness leads to increased testing and diagnosis rates, thereby expanding the market. As healthcare providers and patients become more informed about the risks associated with Helicobacter Pylori, the demand for testing solutions is likely to surge.

Rising Prevalence of Helicobacter Pylori Infections

The increasing incidence of Helicobacter Pylori infections globally drives the demand for testing solutions. According to health statistics, approximately 50% of the world's population is estimated to be infected with this bacterium, which is linked to various gastrointestinal disorders. The Global Helicobacter Pylori Test Market Industry is poised to grow significantly as awareness of these infections rises. With the market projected to reach 3.23 USD Billion in 2024, healthcare providers are increasingly adopting diagnostic tests to manage and treat affected individuals effectively.

Market Segment Insights

By Test Type: Urea Breath Test (Largest) vs. Stool Antigen Test (Fastest-Growing)

The Helicobacter Pylori Test Market is divided into various test types, with the Urea Breath Test holding a significant share as the largest segment. Its non-invasive nature has made it a preferred choice among healthcare providers, leading to widespread adoption. The Stool Antigen Test has emerged as the fastest-growing segment, driven by its increasing use for diagnosis in outpatient settings and at-home testing solutions. This growth signifies a shift towards patient-centric care in the diagnostic process. The demand for non-invasive testing methods continues to rise, fueled by enhanced patient comfort and the efficiency of disease detection. Additionally, innovation in testing technologies and the introduction of rapid test kits are propelling the growth of the Helicobacter Pylori Test Market. As healthcare providers seek to integrate these new solutions into their diagnostic arsenals, both Urea Breath and Stool Antigen Tests are positioned to thrive in this evolving landscape.

Urea Breath Test (Dominant) vs. Stool Antigen Test (Emerging)

The Urea Breath Test is recognized as the dominant test type for Helicobacter Pylori detection due to its accuracy, speed, and comfort for patients. Its non-invasive methodology requires only the consumption of urea-labeled carbon, which is subsequently measured in the breath. This test has solidified its market position as the first choice for physicians. Conversely, the Stool Antigen Test is emerging rapidly within the market, characterized by its ease of use and increasing availability. Patients can conveniently self-administer this test, making it an attractive option for those seeking home testing solutions. This trend reflects the growing preference for accessible medical diagnostics, thereby enhancing the Stool Antigen Test's footprint in the H. Pylori Test Market.

By End User: Hospitals (Largest) vs. Diagnostic Laboratories (Fastest-Growing)

In the Helicobacter Pylori Test Market, hospitals hold the largest share among the end user segments due to their essential role in the diagnosis and treatment of gastrointestinal disorders. They utilize a wide array of testing methods and technologies, solidifying their position as primary providers of H. pylori testing services. In contrast, diagnostic laboratories are experiencing rapid growth, driven by their increased reliance on specialized test kits and advanced diagnostic technologies. Their ability to offer accurate and timely testing services is resulting in a significant rise in market demand. The growth of this segment is bolstered by several factors. The expanding awareness and prevalence of Helicobacter Pylori infections, coupled with advances in testing technologies, are propelling hospitals and laboratories towards adopting more sophisticated diagnostic methods. Additionally, the shift towards point-of-care testing and improved healthcare infrastructures are facilitating the growth of diagnostic laboratories, making them a pivotal player in the market. As healthcare providers continually look to enhance patient outcomes, the demand for effective H. pylori testing will likely persist, thereby stimulating market growth further.

Hospitals (Dominant) vs. Diagnostic Laboratories (Emerging)

Hospitals are regarded as the dominant end-user segment in the Helicobacter Pylori Test Market due to their comprehensive testing capabilities and substantial patient volume. They leverage advanced diagnostic technologies and a wide range of testing modalities to meet the diagnostic needs of a diverse patient population suffering from various gastrointestinal issues. On the other hand, diagnostic laboratories are emerging as a significant player in this market. Their agility in adopting new technologies and specialized test kits enables them to cater to the growing demand for H. pylori testing. These laboratories excel in providing precise results with shorter turnaround times, making them increasingly preferred by healthcare professionals. The collaboration between hospitals and diagnostic laboratories further enhances the overall market growth, fostering a robust healthcare ecosystem.

By Technology: Molecular Diagnostics (Largest) vs. Rapid Test Kits (Fastest-Growing)

In the Helicobacter Pylori Test Market, the distribution of market share among technology segments showcases a competitive landscape. Molecular Diagnostics leads as the largest segment, leveraging advanced techniques for accurate detection. Following closely, Immunoassays and Culture Techniques maintain stable market shares. Rapid Test Kits, though smaller in current share, are gaining traction due to their convenience and speed, catering to a growing demand for point-of-care testing. The growth trends in this segment are significantly influenced by the increasing prevalence of H. pylori infections and the rising awareness of their associated health risks. Technological advancements improve test accuracy and patient outcomes, driving adoption. The demand for rapid diagnostic solutions continues to rise, particularly in developing regions, fostering innovation and expansion in the Rapid Test Kits segment.

Technology: Molecular Diagnostics (Dominant) vs. Rapid Test Kits (Emerging)

Molecular Diagnostics has established itself as the dominant technology in the Helicobacter Pylori Test Market, favored for its high precision and ability to provide comprehensive insights into the infection. This segment employs sophisticated methodologies like PCR, which allow for the detection of H. pylori at a genetic level. On the other hand, Rapid Test Kits are emerging swiftly as a popular alternative due to their convenience and quick results, appealing to both clinicians and patients seeking faster outcomes. These kits utilize immunological techniques that facilitate easy and accessible testing, particularly in outpatient settings. While Molecular Diagnostics remains the gold standard, the appeal of Rapid Test Kits indicates a shift towards more patient-centric care, reflecting evolving market dynamics.

By Sample Type: Stool Sample (Largest) vs. Breath Sample (Fastest-Growing)

The Helicobacter Pylori Test Market reveals a diverse distribution of sample types used in diagnosis. The Stool Sample segment holds the largest market share, primarily due to its non-invasive nature and higher patient preference. Following closely are Blood Samples, which, while less preferred, are still significant in certain clinical settings. Biopsy Samples are limited in use, owing to the invasive procedures involved, thus occupying a smaller market share.

Stool Sample (Dominant) vs. Breath Sample (Emerging)

Stool Samples are the dominant choice in the Helicobacter Pylori Test Market, largely due to their ease of collection and effectiveness in detection. This non-invasive method appeals to a broad demographic, resulting in high adoption rates. Conversely, Breath Samples represent an emerging trend, gaining traction for their rapid results and patient-friendliness. As awareness and demand for quick, accurate testing solutions grow, the Breath Sample segment is anticipated to witness considerable growth, appealing to both healthcare providers and patients looking for less invasive options.

By Distribution Channel: Direct Sales (Largest) vs. Online Sales (Fastest-Growing)

In the Helicobacter Pylori Test Market, the distribution channel landscape is primarily driven by direct sales, which hold a significant share among the various segments. This traditional approach allows manufacturers to establish direct relationships with healthcare providers, ensuring quality control and fostering trust. Online sales, however, are rapidly gaining traction due to advancements in digital marketing and the convenience of e-commerce platforms, capturing a growing segment of consumers looking for accessibility and privacy in testing options.

Direct Sales (Dominant) vs. Online Sales (Emerging)

Direct sales remain the dominant distribution channel in the Helicobacter Pylori Test Market, primarily due to its established presence in traditional healthcare settings. This channel facilitates direct communication with physicians and healthcare institutions, ensuring that end-users receive high-quality tests aligned with clinical guidelines. In contrast, online sales represent an emerging segment, benefiting from increasing smartphone penetration and consumer preference for online shopping. This channel appeals particularly to younger demographics seeking convenience and discretion, driving innovations in online healthcare services and telemedicine integration. As the market evolves, both channels are likely to coexist, catering to distinct consumer needs.

Get more detailed insights about Helicobacter Pylori Test Market

Request Free Sample

Regional Insights

North America : Market Leader in Testing

North America is poised to maintain its leadership in the Helicobacter Pylori test market, holding a significant share of 1620.0. The region's growth is driven by increasing awareness of gastrointestinal diseases, advancements in diagnostic technologies, and supportive healthcare policies. Regulatory bodies are emphasizing early detection and treatment, further propelling market demand. The rising prevalence of H. Pylori infections among the population is also a key factor contributing to this growth. The competitive landscape in North America is robust, featuring major players such as Abbott Laboratories, Thermo Fisher Scientific, and Roche Diagnostics. These companies are investing heavily in research and development to innovate and enhance their product offerings. The presence of advanced healthcare infrastructure and a high level of healthcare expenditure also support the market's expansion. As a result, North America is expected to continue leading the global market for Helicobacter Pylori testing.

Europe : Emerging Market Dynamics

Europe is witnessing a growing demand for Helicobacter Pylori testing, with a market size of 900.0. Factors such as increasing healthcare expenditure, rising awareness of H. Pylori-related diseases, and favorable regulatory frameworks are driving this growth. The European market is characterized by a shift towards non-invasive testing methods, which are gaining traction among healthcare providers. Additionally, government initiatives aimed at improving gastrointestinal health are expected to further boost market demand. Leading countries in this region include Germany, France, and the UK, where the presence of key players like Siemens Healthineers and Bio-Rad Laboratories enhances market competitiveness. The European market is also seeing collaborations between healthcare providers and diagnostic companies to improve testing accuracy and accessibility. As a result, Europe is emerging as a significant player in The Helicobacter Pylori Test.

Asia-Pacific : Rapid Growth Potential

The Asia-Pacific region is experiencing rapid growth in the Helicobacter Pylori test market, with a size of 600.0. This growth is driven by increasing healthcare awareness, rising disposable incomes, and a growing burden of gastrointestinal diseases. Regulatory bodies in countries like Japan and Australia are promoting advanced diagnostic technologies, which are expected to enhance testing capabilities. The region's diverse population and varying healthcare access levels also contribute to the demand for effective testing solutions. Key players in the Asia-Pacific market include Eiken Chemical and Meridian Bioscience, who are focusing on expanding their product portfolios to cater to local needs. Countries such as China and India are emerging as significant markets due to their large populations and increasing healthcare investments. The competitive landscape is evolving, with both local and international companies striving to capture market share in this promising region.

Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region, with a market size of 114.48, presents untapped opportunities in the Helicobacter Pylori test market. The growth is driven by increasing awareness of gastrointestinal health issues, rising healthcare investments, and the need for improved diagnostic solutions. Regulatory initiatives aimed at enhancing healthcare infrastructure are also contributing to market expansion. The region's diverse healthcare landscape presents both challenges and opportunities for market players. Countries like South Africa and the UAE are leading the way in adopting advanced diagnostic technologies. The presence of key players such as Hologic and Genomica is enhancing competition in the market. As healthcare systems in the region continue to evolve, the demand for effective H. Pylori testing solutions is expected to rise, making it a focal point for future investments.

Helicobacter Pylori Test Market Regional Image

Key Players and Competitive Insights

The Helicobacter Pylori Test Market is characterized by a dynamic competitive landscape, driven by increasing awareness of gastrointestinal diseases and the rising prevalence of H. pylori infections globally. Key players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Thermo Fisher Scientific (US) are at the forefront, employing strategies that emphasize innovation and regional expansion. Abbott Laboratories (US) focuses on enhancing its diagnostic portfolio through technological advancements, while Roche Diagnostics (CH) aims to strengthen its market position by investing in research and development to introduce novel testing solutions. Thermo Fisher Scientific (US) appears to be leveraging strategic partnerships to enhance its distribution channels, thereby broadening its market reach. Collectively, these strategies contribute to a competitive environment that is increasingly centered on technological innovation and customer-centric solutions.In terms of business tactics, companies are localizing manufacturing to reduce costs and optimize supply chains, which is particularly relevant in the context of global disruptions. The market structure is moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure allows for a diverse range of products and services, catering to varying customer needs and preferences.

In November Abbott Laboratories (US) announced the launch of a new rapid diagnostic test for H. pylori, which is expected to significantly reduce the time required for diagnosis. This strategic move not only enhances Abbott's product offerings but also positions the company to capture a larger share of the market by addressing the demand for quicker testing solutions. The introduction of this test could potentially lead to improved patient outcomes and increased adoption rates among healthcare providers.

In October Roche Diagnostics (CH) expanded its collaboration with a leading telehealth provider to integrate H. pylori testing into remote patient management systems. This initiative reflects Roche's commitment to digital transformation and highlights the growing trend of telemedicine in diagnostics. By facilitating remote testing, Roche is likely to enhance patient access to essential diagnostic services, thereby reinforcing its competitive edge in the market.

In September Thermo Fisher Scientific (US) acquired a small biotech firm specializing in molecular diagnostics for gastrointestinal pathogens, including H. pylori. This acquisition is indicative of Thermo Fisher's strategy to bolster its capabilities in molecular testing, which is increasingly becoming a preferred method for accurate diagnosis. The integration of advanced molecular technologies could enhance the company's product portfolio and drive future growth.

As of December the Helicobacter Pylori Test Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence (AI) in diagnostic processes. Strategic alliances among key players are shaping the competitive landscape, fostering innovation and enhancing operational efficiencies. Moving forward, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This shift underscores the importance of adaptability and responsiveness in a rapidly changing market environment.

Key Companies in the Helicobacter Pylori Test Market include

Industry Developments

April 2021: A Helicobacter pylori Quick Detection Kit called QuickNaviTM-H.pylori was introduced by Otsuka. The diagnostic test uses immunochromatography to determine whether Helicobacter pylori antigens are present or absent in a stool sample. The test kit, which is intended for use in medical facilities, offers a quick assessment in eight minutes by adding three drops of a sample liquid to the kit.

Future Outlook

Helicobacter Pylori Test Market Future Outlook

The Helicobacter Pylori Test Market is projected to grow at a 5.7% CAGR from 2025 to 2035, driven by increasing prevalence of gastrointestinal disorders and advancements in diagnostic technologies.

New opportunities lie in:

Development of rapid, point-of-care testing kits for remote diagnostics.
Expansion into emerging markets with tailored pricing strategies.
Integration of AI-driven analytics for enhanced test interpretation and patient management.

By 2035, the market is expected to solidify its position as a critical component of gastrointestinal health diagnostics.

Market Segmentation

Helicobacter Pylori Test Market End User Outlook

Hospitals
Diagnostic Laboratories
Home Care Settings
Research Institutions

Helicobacter Pylori Test Market Test Type Outlook

Non-Invasive Test
Invasive Test
Serological Test
Urea Breath Test
Stool Antigen Test

Helicobacter Pylori Test Market Technology Outlook

Molecular Diagnostics
Immunoassays
Culture Methods
Rapid Tests

Helicobacter Pylori Test Market Distribution Channel Outlook

Direct Sales
Online Sales
Retail Pharmacies
Diagnostic Centers

Report Scope

MARKET SIZE 2024	3234.48(USD Million)
MARKET SIZE 2025	3418.91(USD Million)
MARKET SIZE 2035	5952.8(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	5.7% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Million
Key Companies Profiled	Abbott Laboratories (US), Thermo Fisher Scientific (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Bio-Rad Laboratories (US), Hologic (US), Meridian Bioscience (US), Genomica (ES), Eiken Chemical (JP)
Segments Covered	Test Type, End User, Distribution Channel, Technology
Key Market Opportunities	Advancements in non-invasive testing methods enhance accessibility in the Helicobacter Pylori Test Market.
Key Market Dynamics	Rising demand for non-invasive Helicobacter Pylori tests drives innovation and competition among diagnostic manufacturers.
Countries Covered	North America, Europe, APAC, South America, MEA

Market Highlights

Helicobacter Pylori Test Companies

FAQs

What is the current market valuation of the Helicobacter Pylori Test Market?

As of 2024, the market valuation was approximately 3234.48 USD Million.

What is the projected market size for the Helicobacter Pylori Test Market by 2035?

The market is expected to reach a valuation of around 5952.8 USD Million by 2035.

What is the expected CAGR for the Helicobacter Pylori Test Market during the forecast period 2025 - 2035?

The market is anticipated to grow at a CAGR of 5.7% from 2025 to 2035.

Which companies are considered key players in the Helicobacter Pylori Test Market?

Key players include Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, and Siemens Healthineers.

What are the main segments of the Helicobacter Pylori Test Market by test type?

The market segments by test type include Non-Invasive Tests, Invasive Tests, Serological Tests, Urea Breath Tests, and Stool Antigen Tests.

How did the Non-Invasive Test segment perform in terms of valuation?

The Non-Invasive Test segment was valued between 800.0 and 1500.0 USD Million in 2024.

What is the valuation range for the Stool Sample segment in the Helicobacter Pylori Test Market?

The Stool Sample segment had a valuation range of 1200.0 to 2200.0 USD Million in 2024.

Which end-user segment is projected to have the highest valuation in the Helicobacter Pylori Test Market?

The Hospitals segment is projected to have the highest valuation, ranging from 1200.0 to 2200.0 USD Million.

What technologies are utilized in the Helicobacter Pylori Test Market?

Technologies include Molecular Diagnostics, Immunoassays, Culture Techniques, and Rapid Test Kits.

What distribution channels are significant in the Helicobacter Pylori Test Market?

Significant distribution channels include Direct Sales, Online Sales, Retail Pharmacies, and Diagnostic Centers.

Author

Author

Vikita Thakur

Senior Research Analyst

She holds an experience of about 5+ years in market research and business consulting projects for sectors such as life sciences, medical devices, and healthcare IT. She possesses a robust background in data analysis, market estimation, competitive intelligence, pipeline analysis market trend identification, and consumer behavior insights. Her expertise lies in technical Sales support, client interaction and project management, designing and implementing market research studies, conducting competitive analysis, and synthesizing complex data into actionable recommendations that drive business growth.

Co-Author

Kinjoll Dey

Senior Research Analyst

He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.

Get In Touch

Leave a Comment

Certified Researchers

Customize Report

Research Approach

Secondary Research

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed medical journals, clinical publications, epidemiological studies, and authoritative health organizations. Key sources included the US Food & Drug Administration (FDA) 510(k) Premarket Notification Database and De Novo Classification Database for in vitro diagnostic device approvals, European Medicines Agency (EMA) medical device regulations, Centers for Disease Control and Prevention (CDC) Division of Parasitic Diseases and Malaria, World Health Organization (WHO) Global Health Observatory and International Agency for Research on Cancer (IARC) for H. pylori-related gastric cancer statistics, National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Biotechnology Information (NCBI/PubMed) for clinical validation studies, American College of Gastroenterology (ACG) clinical guidelines, European Helicobacter and Microbiota Study Group (EHMSG), Asian Pacific Helicobacter and Microbiota Research (APHMR), Infectious Diseases Society of America (IDSA), Clinical and Laboratory Standards Institute (CLSI) for diagnostic accuracy standards, OECD Health Statistics, EU Eurostat Health Database, and national health ministry reports from Japan (MHLW), China (NHC), and India (MoHFW). These sources were used to collect H. pylori infection prevalence data, diagnostic test procedure volumes, regulatory approval pathways, clinical sensitivity/specificity studies, antimicrobial resistance patterns, and market landscape analysis for immunoassays, molecular diagnostics, urea breath tests, stool antigen tests, and endoscopic biopsy methods.

Primary Research

Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consisted of CEOs, VPs of Research & Development, regulatory affairs directors, and commercial chiefs from diagnostic test manufacturers, IVD companies, and OEM suppliers. The chief of gastroenterology departments, clinical laboratory directors, hospital procurement managers, and medical directors from tertiary care hospitals, reference laboratories, gastroenterology clinics, and point-of-care diagnostic facilities were the demand-side sources. Primary research verified market segmentation by test type (non-endoscopic vs. endoscopic), confirmed product development pipelines and regulatory submission timelines, and collected insights on clinical adoption patterns, reimbursement coding (CPT/HCPCS), pricing strategies, and laboratory workflow integration.

Primary Respondent Breakdown:

By Designation: C-level Executives (32%), Director Level (31%), Others (37%)

By Region: North America (32%), Europe (29%), Asia-Pacific (31%), Rest of World (8%)

Market Size Estimation

Global market valuation was derived through revenue mapping and test volume analysis. The methodology included:

Identification of 40+ key diagnostic manufacturers across North America, Europe, Asia-Pacific, and Latin America

Product mapping across immunoassays (serology/stool antigen), molecular diagnostics (PCR/NAAT), point-of-care rapid tests, urea breath test systems, and endoscopic biopsy-based methods

Analysis of reported and modeled annual revenues specific to H. pylori testing portfolios

Coverage of manufacturers representing 72-78% of global market share in 2024

Extrapolation using bottom-up (test volume × ASP by country/region) and top-down (manufacturer revenue validation) approaches to derive segment-specific valuations by test type (non-endoscopic: urea breath test, stool antigen test, serology; endoscopic: histology, rapid urease test, culture, PCR), technology (immunoassays, point-of-care, molecular diagnostics), and end-user (hospitals & clinics, diagnostic laboratories, others)